BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer
暂无分享,去创建一个
Rosette Lidereau | M. Espié | S. Vacher | I. Bièche | M. Marty | R. Lidereau | F. Lerebours | C. Andrieu | Sophie Vacher | Catherine Andrieu | Ivan Bieche | Florence Lerebours | Marc Espie | Michel Marty
[1] W. Funkhouser,et al. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3 , 2000, Oncogene.
[2] G. Hortobagyi,et al. Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Michael Karin,et al. NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.
[4] M. Karin,et al. NF-kappaB in mammary gland development and breast cancer. , 2003, Journal of mammary gland biology and neoplasia.
[5] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Espié,et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.
[7] Rinat Abramovitch,et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.
[8] H. B. Mann,et al. On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other , 1947 .
[9] A. Itai,et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. , 2006, Cancer research.
[10] M. Mathieu,et al. Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance , 1989, International journal of cancer.
[11] Andreas Sommer,et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .
[12] B. Aggarwal,et al. Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.
[13] E. van Marck,et al. Nuclear Factor-κB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-κB DNA-Binding , 2006, Clinical Cancer Research.
[14] R. Arriagada,et al. [Breast cancers in the evolutive phase]. , 1978, La Revue du praticien.
[15] W. Anderson,et al. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Bertucci,et al. Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.
[17] G. Hortobagyi,et al. Update on the management of inflammatory breast cancer. , 2003, The oncologist.
[18] Kathryn E Luker,et al. Functions of CXCL12 and CXCR4 in breast cancer. , 2006, Cancer letters.
[19] Rosette Lidereau,et al. Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.
[20] H. Pehamberger,et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.
[21] S. Tommasi,et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease , 1989, Cancer.
[22] Luc Y. Dirix,et al. Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis , 2005, Breast Cancer Research and Treatment.
[23] J. Reis-Filho,et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. , 2002, Journal of clinical pathology.
[24] S. Devesa,et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.
[25] Michael Karin,et al. NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.
[26] M. Espié,et al. Two prognostic groups of inflammatory breast cancer have distinct genotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] Sankar Ghosh,et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] I. Bièche,et al. Update on inflammatory breast cancer , 2005, Breast Cancer Research.
[30] W. Funkhouser,et al. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. , 2000, Oncogene.
[31] S. Merajver,et al. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. , 2003, Molecular cancer research : MCR.
[32] Debajit K. Biswas,et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .
[33] B. Aggarwal,et al. Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. , 2004, Cancer treatment and research.
[34] Y. Ben-Neriah,et al. NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.
[35] G. Contesso,et al. Frontiersman of Science , 1994, Environmental Health Perspectives.
[36] E. van Marck,et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] S. Hilsenbeck,et al. Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.
[38] Elisabeth Remy,et al. GeneANOVA-gene expression analysis of variance , 2002, Bioinform..
[39] K. Umezawa,et al. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] G. Sledge,et al. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.
[41] S. Merajver,et al. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. , 2003, Molecular cancer therapeutics.
[42] I. Smith. Goals of Treatment for Patients With Metastatic Breast Cancer. , 2006, Seminars in oncology.